A traditional Chinese medicine polysaccharide with lipid-lowering activity, and a preparation method and application thereof

Abstract

The application discloses a traditional Chinese medicine polysaccharide with lipid-lowering activity and a preparation method and application thereof, relates to the technical field of biological medicine, and the traditional Chinese medicine polysaccharide is neutral uniform polysaccharide ACP1 in allium chinense, the weight-average molecular weight is 17.96 kDa, the polydispersity index is 1.726, is composed of glucose and fructose, and the molar ratio is 2.53%:97.47%. The neutral uniform polysaccharide in allium chinense provided in the application is a new neutral uniform polysaccharide ACP1 extracted from allium chinense, can effectively improve the lipid deposition of AML-12 cells induced by oleic acid, has significant lipid-lowering activity, and is high in safety. The preparation method of the neutral uniform polysaccharide in allium chinense provided in the application is good in repeatability, the obtained neutral uniform polysaccharide is high in purity, and is beneficial to industrial production.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of biological medicine, and more particularly to a traditional Chinese medicine polysaccharide with lipid-lowering activity and a preparation method and application thereof. BACKGROUND

[0002] In recent years, the incidence of cardiovascular diseases continues to rise, and excessive lipid synthesis is one of the core pathological mechanisms. At present, statins are commonly used in clinical practice to control the disease, but long-term use of statins can easily cause liver damage and myopathy. Therefore, it is urgent to find safe and effective new drugs.

[0003] Traditional Chinese medicine Allii Macrostemonis Bulbus is the dried bulb of Allium macrostemon Bunge or Allium chinense G. Don, which has the effects of removing obstruction from meridians of Yang and dispersing, promoting flow of Qi and removing stagnation. Modern studies have confirmed that it has the potential of lowering lipid and anti-atherosclerosis, and is often used in the treatment of cardiovascular diseases. Allii Macrostemonis Bulbus is a medicinal and edible material recorded in Shennong's Herbal Classic, and its bulb is rich in polysaccharides. At present, the research on the cardiovascular disease treatment active substances of Allii Macrostemonis Bulbus focuses on the polysaccharides of Allium macrostemon bulb, and whether the polysaccharides of Allii Macrostemonis Bulbus have activity is still unclear. A small amount of literature has studied the extraction and purification process of Allium macrostemon polysaccharides (for example, Chinese invention patent with application number 202411273222.0), but the research on Allii Macrostemonis Bulbus polysaccharides has not been reported.

[0004] Therefore, it is a technical problem to be solved by those skilled in the art to extract polysaccharides with high purity and lipid-lowering activity from Allii Macrostemonis Bulbus, so as to realize the development and treatment of cardiovascular disease drugs. SUMMARY

[0005] Therefore, the present application provides a traditional Chinese medicine polysaccharide with lipid-lowering activity and a preparation method and application thereof.

[0006] In order to achieve the above-mentioned purpose, the present application adopts the following technical solutions:

[0007] A traditional Chinese medicine polysaccharide with lipid-lowering activity, wherein the traditional Chinese medicine polysaccharide is Allii Macrostemonis Bulbus neutral homogeneous polysaccharide ACP1, the weight average molecular weight is 17.96 kDa, the polydispersity index is 1.726, the traditional Chinese medicine polysaccharide is composed of glucose and fructose, and the molar ratio is 2.53%:97.47%.

[0008] As a preferred technical scheme, the neutral homogeneous polysaccharide main chain of the allium is composed of →6)-β-D-Fruf-(2→ and →1,6)-β-D-Fruf-(2→ and one internal →6)-α-D-Glcp-(1→, and the side chain is composed of →1)-β-D-Fruf-(2→ and β-D-Fruf-(2→.

[0009] As a more preferred technical scheme, the main structure of the neutral homogeneous polysaccharide of the allium is as follows

[0010] .

[0011] Another object of the present application is to provide a preparation method of the traditional Chinese medicine polysaccharide with lipid-lowering activity.

[0012] S1: preparing allium crude polysaccharide ACP: fresh allium bulb is cut into pieces, defatted with ethanol to obtain residue; the obtained residue is subjected to water extraction to obtain an extraction liquid; the extraction liquid is concentrated, and then precipitated with ethanol, and the obtained precipitate is the allium crude polysaccharide ACP;

[0013] S2: preparing allium neutral homogeneous polysaccharide ACP1: the allium crude polysaccharide ACP is redissolved with water, and the protein is removed by papain combined with Sevage method and the supernatant is collected; ethanol is added again for precipitation, and the precipitate is washed with an organic solvent; after redissolving with water, dialysis is performed, and the obtained dialysate is subjected to chromatography purification by anion exchange column chromatography, eluted with water and the eluate is collected, and the obtained eluate is dried to obtain the allium neutral homogeneous polysaccharide ACP1.

[0014] As a preferred technical scheme, S1 for preparing the allium crude polysaccharide ACP is specifically as follows: the fresh allium bulb is cut into pieces, and then 7 times the amount of 95% ethanol solution is added to extract for 2 hours by reflux extraction; then the residue is taken out, 7 times the amount of water is added, and the mixture is extracted for 2 times at 85 ℃, each for 2 hours; the two extraction liquids are combined and concentrated, and then 80% ethanol is used to precipitate at 4 ℃ for 24 hours, and the precipitate is collected.

[0015] As a preferred technical scheme, the S2 preparing the allium chinense neutral homogeneous polysaccharide ACP1 is specifically as follows: the allium chinense crude polysaccharide obtained in S1 is added into water for redissolution, then papain is added, and the solution is kept at 60 DEG C for 5 hours; the protein in the solution is removed by using the Sevage method, the ratio of chloroform to n-butanol is 5:1, the solution is left to stand for 2 hours, then centrifuged, the supernatant is taken, and the above steps are repeated for 5 times; the supernatant is added with anhydrous ethanol to adjust the ethanol concentration of the solution to 80% for precipitation, then the precipitate is washed with anhydrous ethanol and acetone organic solvents in sequence; the precipitate is redissolved with water, and dialysis is performed by using a dialysis bag with a molecular weight cut-off of 3.5 kDa. The dialysate is subjected to chromatography purification by using a DEAE cellulose DE-52 anion exchange column, water is used for elution, the flow rate is 1 mL / min, the elution volume is 350 mL, the eluate is collected, and all the water eluate obtained is concentrated and dried to obtain the allium chinense neutral homogeneous polysaccharide.

[0016] Another object of the present application is to provide the application of the above-mentioned Chinese medicine polysaccharide with lipid-lowering activity or the above-mentioned Chinese medicine polysaccharide with lipid-lowering activity prepared by the above-mentioned preparation method in the preparation of lipid-lowering drugs.

[0017] Beneficial effects:

[0018] The allium chinense neutral homogeneous polysaccharide provided by the present application is a new neutral homogeneous polysaccharide ACP1 extracted from allium chinense, which is mainly composed of fructose, does not contain acidic groups or basic groups in the fine structure, can effectively improve the lipid deposition of AML-12 cells induced by oleic acid, and has significant lipid-lowering activity.

[0019] The preparation method of the allium chinense neutral homogeneous polysaccharide provided by the present application has good repeatability, and the obtained neutral homogeneous polysaccharide has high purity, which is beneficial to industrial production. BRIEF DESCRIPTION OF DRAWINGS

[0020] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the following will briefly introduce the drawings needed to be used in the embodiments or prior art description. Obviously, the drawings in the following description are only embodiments of the present application, and other drawings can also be obtained by those skilled in the art without creative labor on the basis of the provided drawings.

[0021] Figure 1 HPGPC-MALLS-RID chromatogram of the allium chinense neutral homogeneous polysaccharide (ACP1) in Example 2;

[0022] Figure 2 UV spectrum of the neutral allium chinense homogeneous polysaccharide (ACP1) in Example 2;

[0023] Figure 3 Infrared spectrum of the neutral allium chinense homogeneous polysaccharide (ACP1) in Example 2;

[0024] Figure 4 The neutral allium homopolysaccharide (ACP1) in Example 2 1 H NMR spectrum;

[0025] Figure 5 The neutral allium homopolysaccharide (ACP1) in Example 2 13 C NMR spectrum;

[0026] Figure 6 This is a schematic diagram of the main structure of the allium neutral homogeneous polysaccharide (ACP1) in Example 2;

[0027] Figure 7 This study describes the therapeutic effect of homogeneous polysaccharide (ACP1) from *Allium macrostemon* (CN) on an oleic acid-induced lipid deposition model in AML-12 cells, as described in Example 3. CN was the control group, MOD was the model group, FB was the positive control group (fenofibrate), and the remaining groups contained different doses of homogeneous polysaccharide (ACP1). ### p<0.001 vs CN; *** p<0.001 vs MOD). Detailed Implementation

[0028] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0029] Example 1: Preparation of neutral homogeneous polysaccharide from Allium macrostemon

[0030] (1) Preparation of crude polysaccharide from Allium macrostemon (ACP)

[0031] 10 kg of fresh Allium tuberosum bulbs were chopped and extracted with 70 L of 95% ethanol solution using the reflux extraction method for 2 hours. The residue was then extracted twice with 7 times the amount of water at 85 °C for 2 hours each time. The two extracts were combined and concentrated to 4 L. Then, 16 L of anhydrous ethanol was added and the mixture was allowed to stand at 4 °C for 24 hours. The precipitate was collected, and the obtained precipitate was Allium tuberosum crude polysaccharide (ACP). The crude drug yield was 23.55%.

[0032] (2) Preparation of neutral homogeneous polysaccharide (ACP1) from Allium macrostemon

[0033] The ACP obtained in the above step was dissolved in 2 L of water, and then 100 g of papain was added, and the mixture was incubated at 60 °C for 5 hours. The protein was removed by the Sevage method, 400 mL of chloroform and 80 mL of n-butanol were added, and the mixture was mixed uniformly, and then was allowed to stand for 2 hours and was centrifuged. The supernatant was collected, and the operation was repeated 5 times. Then, the ethanol concentration of the solution was adjusted to 80% by adding anhydrous ethanol, and the precipitate was precipitated. The precipitate was washed with anhydrous ethanol and acetone organic solvents. The precipitate was dissolved in water, and was dialyzed by using a dialysis bag with a molecular weight cut-off of 3.5 kDa. The dialysate obtained was subjected to chromatography on a DEAE cellulose DE-52 anion exchange column, and was eluted with water at a flow rate of 1 mL / min, and the elution volume was 350 mL. The eluate was collected, and the water eluate obtained was concentrated and dried to obtain ACP1, and the crude drug yield was 3.2%.

[0034] Example 2 Structural characterization of ACP1

[0035] 1. The ACP1 obtained in Example 1 was analyzed for molecular weight and purity by HPGPC-MALLS-RID chromatography.

[0036] The chromatographic column used was a combination of Shodex OH-pak SB-805 HQ (300×8 mm) and Shodex OH-pak SB-803 HQ (300×8 mm), the mobile phase was 0.1 M NaNO3 aqueous solution containing 0.02% NaN3, the column temperature was 45 °C, the flow rate was 0.6 mL / min, and the injection volume was 100 μL. The dn / dc value of the component in 0.1 M NaNO3 aqueous solution containing 0.02% NaN3 was 0.141 mL / g.

[0037] The results are shown in the accompanying Figure 1 The polysaccharide obtained in Example 1 was a single symmetrical peak, indicating that it was a homogeneous polysaccharide, and the HPGPC-determined homogeneous monosaccharide purity was 99.2%. In this example, the concentration information of the sample was detected by the refractive index detector according to the refractive intensity, the light scattering information of the macromolecule was detected by the multi-angle laser light scattering instrument, and the corresponding molecular weight was calculated according to the Mark-Houwink Equation. The chromatographic data were processed by using the software ASTRA 6.1, the detected retention time (Time, min) was used as the abscissa, and the molar mass Molar Mass (g / mol) was used as the ordinate to make an absolute molecular weight analysis graph, and the weight average molecular weight (Mw) of the homogeneous polysaccharide (ACP1) obtained in Example 1 was calculated to be 17.96 kDa, and the polydispersity index (Mw / Mn) was 1.726.

[0038] 2. The UV-Vis spectrum of the neutral uniform polysaccharide (ACP1) obtained in Example 1 was analyzed by using a UV spectrophotometer.

[0039] The UV-Vis spectrum of the neutral uniform polysaccharide (ACP1) was detected by using a UV spectrophotometer in the range of 200 ~ 800 nm, and the results are shown in Figure 2. Figure 2 As shown in Figure 2, the neutral uniform polysaccharide (ACP1) obtained in Example 1 had no obvious absorption peaks at 260 nm and 280 nm, which indicated that it did not contain protein substances or nucleic acids.

[0040] 3. The IR spectrum of the neutral uniform polysaccharide (ACP1) obtained in Example 1 was analyzed by using an infrared spectrometer.

[0041] The IR spectrum of the neutral uniform polysaccharide (ACP1) was detected by using an infrared spectrometer in the range of 4000 ~ 400 cm -1 , and the results are shown in Figure 3. Figure 3 As shown in Figure 3, the functional group analysis of the neutral uniform polysaccharide (ACP1) obtained in Example 1 showed that the absorption peaks at 3410 cm -1 and 1640 cm -1 were attributed to the O-H stretching vibration and bending vibration, respectively; the absorption peaks at 2937 cm -1 and 1500 ~ 1200 cm -1 were attributed to the C-H stretching vibration and bending vibration, respectively; the absorption peaks at 1128 cm -1 and 1029 cm -1 indicated that the neutral uniform polysaccharide (ACP1) contained furanose residues; and the absorption peaks at 930 cm -1 and 818 cm -1 were attributed to fructose with β-type glycosidic bonds.

[0042] 4. The monosaccharide composition of the neutral uniform polysaccharide (ACP1) obtained in Example 1 was analyzed. 2.41 mg of the neutral uniform polysaccharide (ACP1) was added with 1 mL of 2M trifluoroacetic acid solution, heated at 60 ℃ for 1 hour, and then blown dry under nitrogen. The sample was washed with methanol and blown dry again, and the washing process was repeated for 2-3 times. The sample was dissolved in an appropriate amount of sterile water, transferred into a chromatographic bottle, and then detected. The chromatographic column was Dionex™ CarboPac™ PA-20 (150*3.0 mm, 10 μm), the mobile phase A was H2O, the mobile phase B was 0.1 M NaOH, the mobile phase C was 0.1 M NaOH and 0.2 M NaAc, the flow rate was set at 0.5 mL / min, the injection amount was set at 5 μL, and the column temperature was set at 30 ℃. The electrochemical detector was used for detection, and it was found that the monosaccharide composition of the neutral uniform polysaccharide (ACP1) included glucose and fructose, as shown in Table 1.

[0043] Table 1 Monosaccharide composition of ACP1

[0044]

[0045] 5. Methyl analysis of ACP1 in Example 1

[0046] After the sample was subjected to methylation, hydrolysis, reduction and acetylation in turn, the results determined by GC-MS were compared with the standard mass spectrum library. The GC-MS determination conditions were as follows: a BPX70 chromatographic column (30 m x 0.25 mm x 0.25 μm, SGE, Australia) was used, the injection amount was 1 μL, the split ratio was 10:1, the carrier gas was high-purity helium, the flow rate was 1.5 mL / min; the initial temperature of the column oven was 140 °C, which was maintained for 2 min, and then increased to 230 °C at a rate of 3 °C / min, and maintained for 3 min; the ion source temperature was 200 °C, the MS quadrupole rod temperature was 110 °C, the ionization energy was 50 eV, the transfer line temperature was 210 °C, and the mass scan range (m / z) was 50-350.

[0047] Through the methyl analysis, it can be known that ACP1 has various glycosidic bonds as shown in Table 2.

[0048] Table 2 Methylated glycol acetate analysis results of ACP1

[0049]

[0050] Through the above methyl analysis, it can be known that ACP1 has a repeatable unit structure, the main chain of which is composed of →6)-β-D-Fruf-(2→ and →1,6)-β-D-Fruf-(2→ and an internal →6)-α-D-Glcp-(1→, and the side chain is composed of →1)-β-D-Fruf-(2→ and β-D-Fruf-(2→.

[0051] 6. Nuclear magnetic resonance spectrum analysis of ACP1 in Example 1

[0052] 30 mg of ACP1 was weighed and dissolved in 0.5 mL of heavy water, and was collected by a nuclear magnetic resonance instrument at 600 MHz 1 HNMR spectrum and 13 C NMR spectrum.

[0053] The results are shown in the following figures: Figure 4 1 ​HNMR spectrum showed that the end group hydrogen of glucose was δ = 5.36 ppm, and fructose was ketose without end group hydrogen signal; as shown in the attached Figure 5 , 13 CNMR spectrum showed that the end group carbon signal of fructose was δ = 102 ~ 105 ppm, and the end group carbon signal of glucose was δ = 92.02 ppm. The structure of ACP1 could also be verified by the above nuclear magnetic resonance spectrum data. The main structure of ACP1 is shown in the attached Figure 6 .

[0054] In summary, ACP1 prepared in Example 1 is a neutral homogeneous polysaccharide, with a weight average molecular weight (Mw) of 17.96 kDa and a polydispersity index (Mw / Mn) of 1.726. The infrared spectrum shows that it has typical polysaccharide absorption peaks, including a hydroxyl absorption peak at 3410 cm -1 , β-type glycosidic bond fructose absorption peaks at 930 cm -1 and 818 cm -1 , and no carbonyl absorption peak at 1700 cm -1 , consistent with the absence of absorption peaks at a wavelength of 280 nm in the ultraviolet spectrum; GC-MS analysis results show that the main chain of ACP1 is composed of →6)-β-D-Fruf-(2→ and →1,6)-β-D-Fruf-(2→ and an internal →6)-α-D-Glcp-(1→, and the side chain is composed of →1)-β-D-Fruf-(2→ and β-D-Fruf-(2→, which is consistent with the result of monosaccharide composition analysis.

[0055] Example 3 Verification of the activity of ACP1

[0056] In this example, the effect of ACP1 on blood lipids was investigated using an oleic acid-induced AML-12 cell lipid deposition model: AML-12 cells (Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences) in the logarithmic growth phase were seeded in 6-well plates at a density of 1 × 10 4The 96-well plates were seeded with a certain density of holes, the control group (CN) was added with 1% FBS-DMEM / F12 medium, the model group (MOD), the positive drug group (FB), and the different concentrations of ACP1 drug groups were added with 1% FBS-DMEM / F12 medium containing 1 mM oleic acid, and were cultured in a 37 ℃ incubator for 24 hours. Subsequently, the supernatant of each well was discarded, the control group and the model group were added with 2% FBS-DMEM / F12 medium, the positive drug group was added with 2% FBS-DMEM / F12 medium containing 100 μM fenofibrate, and each drug group was added with 2% FBS-DMEM / F12 medium containing ACP1 0.125 mg / mL, 0.25 mg / mL, 0.5 mg / mL, 1.0 mg / mL, and 2.0 mg / mL, respectively, and was cultured in a 37 ℃ incubator for 24 hours.

[0057] After the incubation, the supernatant of each well was discarded, and 100 μL of PBS was added for rinsing once and then discarded. 100 μL of 4% fixing solution was added to each well, and was fixed at 4 ℃ for 30 min and then discarded. 100 μL of PBS was added for rinsing once and then discarded. Subsequently, 20 μL of 0.3% oil red solution was added to each well, and was dyed in the dark for 15 min and then discarded. 100 μL of PBS was added for rinsing twice and then discarded. Finally, 100 μL of DMSO was added to each well, and was mixed for 10 min by using a plate mixer. The OD value at 358 nm of each group was determined by using an enzyme-labeled instrument, so as to indirectly quantify the deposition level of neutral lipids (mainly triglycerides and cholesteryl esters) in the cells.

[0058] The results are shown in the accompanying Figure 7 The ACP1 can effectively improve the lipid deposition of AML-12 cells induced by oleic acid at a concentration of 0.125-2.0 mg / mL, has significant lipid-lowering activity, and is safer as a natural biological macromolecule.

[0059] The embodiments in the specification are described in a progressive manner, and each embodiment focuses on the difference from other embodiments. The same or similar parts of each embodiment can be referred to each other.

[0060] The above description of the disclosed embodiments enables a person skilled in the art to implement or use the present application. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to these embodiments shown herein, but will conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A traditional Chinese medicine polysaccharide having lipid-lowering activity, characterized in that, The traditional Chinese medicine polysaccharide is Allium chinense neutral homogeneous polysaccharide ACP1, the weight average molecular weight is 17.96 kDa, the polydispersity index is 1.726, is composed of glucose and fructose, and the molar ratio is 2.53%:97.47%; The Allium chinense neutral homogeneous polysaccharide ACP1 main chain is composed of →6)-beta-D-Fruf-(2→ and →1,6)-beta-D-Fruf-(2→ and an internal →6)-alpha-D-Glcp-(1→, and the side chain is composed of →1)-beta-D-Fruf-(2→ and beta-D-Fruf-(2→; And, the preparation method of the traditional Chinese medicine polysaccharide comprises the following steps: S1: preparing Allium crude polysaccharide ACP: fresh Allium scale bulbs are cut into pieces, defatted by ethanol, and residues are obtained; the obtained residues are water-extracted to obtain an extraction liquid; the extraction liquid is concentrated, and then precipitated by ethanol, and the obtained precipitate is the Allium crude polysaccharide ACP; S2: preparing Allium chinense neutral homogeneous polysaccharide ACP1: the Allium crude polysaccharide ACP is redissolved with water, protein is removed by papain combined with Sevage method, and the supernatant is collected; ethanol is added again for precipitation, and the precipitate is washed with an organic solvent; after redissolving with water and dialysis, the obtained dialysate is chromatographically purified by an anion exchange column, eluted with water, and the water eluate is collected; the obtained eluate is concentrated and dried to obtain the Allium chinense neutral homogeneous polysaccharide ACP1.

2. The traditional Chinese medicine polysaccharide with lipid-lowering activity according to claim 1, characterized in that, The main structure of the Allium chinense neutral homogeneous polysaccharide is as follows 。 3. The preparation method of the traditional Chinese medicine polysaccharide with lipid-lowering activity according to claim 1 or 2, characterized in that, Comprise the following steps: S1: preparing Allium crude polysaccharide ACP: fresh Allium scale bulbs are cut into pieces, defatted by ethanol, and residues are obtained; the obtained residues are water-extracted to obtain an extraction liquid; the extraction liquid is concentrated, and then precipitated by ethanol, and the obtained precipitate is the Allium crude polysaccharide ACP; S2: preparing Allium chinense neutral homogeneous polysaccharide ACP1: the Allium crude polysaccharide ACP is redissolved with water, protein is removed by papain combined with Sevage method, and the supernatant is collected; ethanol is added again for precipitation, and the precipitate is washed with an organic solvent; after redissolving with water and dialysis, the obtained dialysate is chromatographically purified by an anion exchange column, eluted with water, and the water eluate is collected; the obtained eluate is concentrated and dried to obtain the Allium chinense neutral homogeneous polysaccharide ACP1.

4. The method of claim 3, wherein the preparation method of the Chinese medicine polysaccharide with lipid-lowering activity is characterized by, S1 preparing Allium crude polysaccharide ACP specifically: after fresh Allium scale bulbs are cut into pieces, 7 times of 95% concentration ethanol solution is added to extract for 2 hours by reflux extraction; then the residues are taken out, 7 times of water is added, and the mixture is extracted for 2 hours at 85 DEG C; the two extraction liquids are combined and concentrated, then 80% ethanol is used to precipitate at 4 DEG C for 24 hours, and the precipitate is collected.

5. The method of claim 3, wherein the preparation method of the Chinese medicine polysaccharide with lipid-lowering activity is characterized by, S2 is to prepare the Allium chinense neutral homogeneous polysaccharide ACP1, which is specifically as follows: the Allium chinense crude polysaccharide obtained in S1 is dissolved in water, and then papain is added, and the solution is incubated at 60 ℃ for 5 hours; the protein in the solution is removed by Sevage method, the ratio of chloroform to n-butanol is 5:1, and the solution is centrifuged after being left to stand for 2 hours; the supernatant is taken, and the operation is repeated 5 times; anhydrous ethanol is added to the supernatant to adjust the ethanol concentration of the solution to 80% for precipitation, and then the precipitate is washed with anhydrous ethanol and acetone organic solvents in sequence; the precipitate is redissolved in water, and dialysis is performed by using a dialysis bag with a molecular weight cut-off of 3.5 kDa; the obtained dialysate is subjected to chromatography purification by using a DEAE cellulose DE-52 anion exchange column, water is used for elution, the flow rate is 1 mL / min, the elution volume is 350 mL, the eluate is collected, and the obtained all water eluate is concentrated and dried to obtain the Allium chinense neutral homogeneous polysaccharide.

6. The application of the Chinese medicinal polysaccharide with lipid-lowering activity as claimed in claim 1 or 2 or the Chinese medicinal polysaccharide with lipid-lowering activity prepared by the preparation method as claimed in any one of claims 3-5 in the preparation of a lipid-lowering drug.

Images